



June 16, 2017

In an ongoing effort to provide appropriate, affordable, healthcare options to our members, Willamette Valley Community Health CCO will be making several changes to the current formulary.

All formulary changes, additions and removals are thoroughly investigated, reviewed and approved by the WVP Health Authority Pharmacy & Therapeutics Committee. This Committee is comprised of several providers representing multiple specialties and clinics from our community. These recommendations were based on utilization, pharmacokinetic information and cost data.

We value your partnership as we continue to work toward our mutual goal of delivering the highest quality healthcare while ensuring affordability and accessibility. If you are interested in participating in the WVP P & T Committee please contact the WVP Clinical Pharmacists at 503-371-7701 for more information.

WVCH Formulary Additions Effective 6/17/17				
Name	Strength	Dosage Form	Route	Change
Tobramycin Nebulizer Solution	300 mg/5 ml	Nebulizer solution	Inhlation	Adding to formulary with PA criteria
Xifaxan	200 mg and 550 mg	Tablet	Oral	Adding to formulary with PA criteria

WVCH Formulary Removals Effective 8/1/17			
Name	Strength	Dosage Form	Route
Cephalexin	750 mg	Capsules	Oral
Cephalexin	500 mg	Tablets	Oral
Cefaclor	125mg/5ml, 250 mg/5ml, 375mg/5ml	Suspension	Oral
Cefaclor	250 mg, 500 mg	Capsules	Oral
Cefixime	100mg/5ml, 200 mg/5ml	Suspension	Oral
Cefixime	100 mg, 200 mg	Chewable tablets	Oral
Cefixime	400 mg	Capsule	Oral
Cefixime	400 mg	Tablets	Oral



Lantus (insulin glargine) (Bio similar Basaglar was added to the WVCH formulary effective 05.01.2017)	100 units/ml	Vial and Pen (Solostar)	Injection
--	---------------------	--------------------------------	------------------

WVCH Formulary Additions Effective 8/1/17				
Name	Strength	Dosage Form	Route	Change
Levemir (Insulin Detemir)	100 units/ml	Solution	Injection	PA for new starts only